Member Info for Laura2022

The potential contract value from the Material Opportunities for the financial year ending 31 March 2026 is approximately £15 million, and it is expected that there would be follow-on sales of units, software and support. There have been regular ongoing discussions with these potential customers and significant milestones are scheduled for the fourth quarter of the financial year ending 31 March 2025.

As at the date of this announcement, the Group does not have confirmation from these potential customers as to when purchase orders for the Material Opportunities will be entered into, if at all.

The Group's current cash balances as at the date of this announcement total approximately £1.5 million. The Group has no debt, other than a total lease liability of £0.6 million. The Group currently has in place an undrawn overdraft facility of £0.95 million which expires on 31 May 2025. If none of the Material Opportunities are converted to orders, the Board expects the cash resources of the Group to last until approximately the end of May 2025.

Worth a punt as last time did 50%

another example of Pod Point taking the lead in Energy Flex as the first company to take advantage of this new regulation. We have the largest Energy Flex enabled chargepoint network in the UK, with over a quarter of a million chargers, providing significant scale and relevance to the Grid. Pod Point has delivered a huge amount of progress in Energy Flex over the last 12 months, and we have further exciting plans for this emerging market in the next 12 months."

Oldgdog

£6k 1.1125p

£7k NT

The number of securities in issue is 161,059,012 ordinary shares of 1 pence each.

Major Shareholders

As at 27 September 2024 the Company was aware of the following shareholdings

representing 3% or more in the Company’s existing issued Ordinary Share Capital.

Name Number of Ordinary

shares

% of share

capital

Schroder Investment Management 26,862,539 16.68

Canaccord Wealth Management 24,500,000 14.59

Pentland Capital Ltd 17,010,197 10.56

Herald Investment Management 15,329,712 9.52

Tom Black 13,272,540 8.24

Janus Henderson Investors 12,089,061 7.51

Lombard Odier Asset Mgt 10,645,573 6.61

Invesco Perpetual Investment Management 10,444,328 6.48

Thanks KingH

Looking very blue

At 1.08p

Still reducing..gives more chance to buy at this cheap level

Very useful and informative article

Thanks PP

Only about £1000 available then it's negotiated order

MODE need cash as I told you with your old account last week

Blowdog

As debull says, some good summary from KingHomer and Basilalderman

50%+ move this week, maybe more ?

Now seller cleared and buys stepped in and with RSI/MACD breakout emerging

New Evaluation and Option Agreement

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, and Altus Formulation Inc ("Altus") a Canada based drug development and delivery company, have entered into an evaluation and option agreement to determine the value of Altus' SmartCelle drug delivery technologies and novel anti-inflammatory compounds in the treatment of cancer (the "Agreement") for an initial twelve month period.

Under the Agreement, ValiRx will assess the SmartCelle platform's ability to enhance the solubility, potency and targeting of a series of drug candidates including ValiRx's CLX001 cytolytic peptide and Altus' novel CB2 agonist TA-A001. The evaluation will be performed on a range of Patient Derived Cells (PDCs) by ValiRx's subsidiary Inaphaea BioLabs, with lead candidates then being tested in vivo through collaborative partners to assess safety, biodistribution and efficacy. ValiRx has an option to license the technologies for the treatment of certain cancers.

Take your own advice?

aimgambler123

Posted in: GBP

Posts: 2,047

Price: 0.1725

No Opinion

RE: Good time to buy in soon17 Jan 2025 11:04

Who's this MH01 clown? Spending all day on here trying to trash a share he doesn't own. Get a life ffs!

Physiomics plc

1,783 followers

7h

We’re heading to Boston! ✈️

The 8th Annual DDR Inhibitors Summit kicks off tomorrow, and we’re excited to join industry leaders exploring the latest breakthroughs in DDR therapies.

At Physiomics plc, we use PKPD and QSP-based approaches to model the effects of DDR inhibitors on tumour growth. This enables us to predict optimal dosing regimens and scheduling, balancing efficacy and toxicity. Our expertise in model-informed drug development (MIDD) ensures our clients can move confidently into clinical trials, reducing risk and accelerating progress.

If you're attending, be sure to connect with our Head of Business Development, Hayley Close, to discuss how we can support your DDR programme.

Ask price at the time was 0.165p .so paid well above

13:55:53 0.17 10,000,000 Unknown* 17.00k

From this afternoon

Day 1 breakout today and still incredibly oversold

Moving quickly